Top Pharma & Biotech Deals, Investments, M&As in August 2018
16. September 2018
In August, the biotech boom of 2018 continued unabated and the Wall Street Journal reported that investment banks have lured top biotech analysts with guaranteed pay packages of USD 3 million or more.
At this time of the year, equity analysts who assess companies and write reports that help investors gauge prospects and interpret news will certainly have their hands full as investments into pharma and biotech companies continue to grow at a rapid pace.
Leading the pack in August was US-based Emergent BioSolutions which made two acquisitions to stay on track of its growth plan to achieve US$ 1 billion in revenue by 2020.
While European businesses have had a long-established practice of taking off during the months of July or August, last month two German startups — AffimedNV and Mologen AG — announced big ticket deals which could result in multi-billion dollar payouts. And Hong Kong continued its efforts to lure overseas-listed firms to conduct secondary share offerings in the financial hub.